Clinical Trials Logo

Retinitis clinical trials

View clinical trials related to Retinitis.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 4

NCT ID: NCT00017784 Active, not recruiting - HIV Infections Clinical Trials

Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to make valganciclovir available, before it is approved for marketing, to HIV-infected patients who have cytomegalovirus (CMV) retinitis (eye infection) and cannot take drugs by injection. This study also will look at the safety of using valganciclovir as starting and/or ongoing therapy. CMV can cause serious AIDS-related infections in patients with HIV. Drugs that are effective against CMV eye infections can be given only by injection; this calls for a thin tube to be placed into a vein in the chest so that the patient is not put through getting too many needle sticks. An experimental drug, valganciclovir, is similar to 1 of these approved drugs, ganciclovir, but is more convenient and easier to use since it can be taken by mouth. Once in the body, valganciclovir changes to ganciclovir. Studies have shown that valganciclovir tablets can result in the same level of ganciclovir in the blood as ganciclovir injection.

NCT ID: NCT00002384 Active, not recruiting - HIV Infections Clinical Trials

A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Start date: n/a
Phase: N/A
Study type: Interventional

Incomplete Closed Protocol

NCT ID: NCT00002301 Active, not recruiting - HIV Infections Clinical Trials

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir

Start date: n/a
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of foscarnet induction treatment of cytomegalovirus (CMV) retinitis in AIDS patients who have previously suffered severe dose-limiting ganciclovir-related myelosuppression, who are ineligible for ganciclovir treatment due to myelosuppression or who have clearly failed to have a therapeutic response to ganciclovir therapy. To assess the duration of clinical response. To evaluate the effect on quantitative CMV cultures of blood and urine. To determine the effect on recovery of HIV p24 antigen capture direct from plasma.